The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology TherapeuticsHosted By : Andrea Charles
November 6, 2012
predictive toxicology | preclinical considerations | computational biology | clinical drug development | novel oncology therapeutics | Ken Olivier | Merrimack Pharmaceuticals
About this Podcast...
In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development.
Have Your Say
Rate this feature and give us your feedback in the comments section below
to get access to this White Paper
comments powered by Disqus
Don't Let Geopolitical Developments in Eastern Europe Derail Your Clinical Trials - Applying Local Knowledge
June 10, 2014
Global Pharmaceutical Serialisation and Track & Trace Open House
March 18, 2014
Comparators – New GDP Rules, Emerging Markets, to Site Distribution and Partnerships - How Will They Affect Your Comparator Procurement
January 15, 2014